Latest News

An expert panel failed to reach consensus on how to treat some patients with severe hemophilia A, suggesting that further study is needed where the optimal treatment remains equivocal, according to research published in the Journal of Blood Medicine. Hemophilia A is linked with a reduced quality of life (QoL)...
New York, New York – Because bleeding from the reproductive tract is a naturally occurring event during menstruation and childbirth, women who exhibit menorrhagia, or excessive bleeding after their menstrual cycle, may have underlying diseases that are underdiagnosed. In order to address important issues related to the diagnosis and management...
Extended induction chemotherapy with topotecan, cyclophosphamide, and etoposide does not improve event-free survival (EFS) and overall survival (OS) in patients with high-risk neuroblastoma, and it increases the number of toxic side effects, according to findings published in the Annals of Oncology. The open-label, prospective, randomized controlled phase 3 NB2004-HR trial (ClinicalTrials.gov...
Extensive examination of lymph nodes and node stations appeared to be crucial to predicting accurate staging and survival outcomes in patients with pure-solid, non-small cell lung cancer (NSCLC) who underwent lobectomy and ipsilateral lymphadenectomy, according to the results of a study published in the Journal of the National Comprehensive Cancer Network....
NEW YORK, NY — EyeDura Therapeutics Inc., a leader in preservative-free, topical sustained-release ophthalmic therapies, today announced initiating preclinical efficacy studies with the Singapore Eye Research Institute (SERI) towards continued development of its lead insulin-based topical eye drop treatment for neurotrophic keratitis (NK), a rare eye disease affecting approximately 71,000...
WATERTOWN, Mass.— EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet...